In order to investigate how GYP exerts its anti-LC effects by regulating metabolites and metabolic pathways as well as enhancing the anti-lung cancer effects of chemotherapeutic agents, the relative contents of STAT3, EGFR, MAPK14, and TYMS between the six groups were analyzed by western blot (Figure 11). The gene discussed is GYPB; the disease is lung carcinoma.